Pharmaceutical manufacture: new standards and best practice

Published: 14-Jan-2016

The 23rd annual Pharmig conference, held in Nottingham in November 2015, brought together expert microbiologists, regulatory inspectors and delegates to discuss recent changes to regulatory guidance, as well as hot topics in biofilm remediation, cleaning and environmental monitoring. Susan Birks reports

You need to be a subscriber to read this article.
Click here to find out more.

There has been increased regulatory focus on data integrity recently and, as Andrew Hopkins reminded delegates, data provides the foundation for people’s trust in medicines. Hopkins, a Senior GMP Inspector with the UK Medicines and Healthcare Products Regulatory Agency (MHRA), explained that Quantitative Risk Management is based on accurate feedback and the consequences of not getting it right can cause patient harm or product shortages and create a considerable financial cost for the companies concerned.

Hopkins gave a regulator’s perspective on data integrity, defining it as ‘the extent to which all data are complete, consistent and accurate throughout the data lifecycle – covering everything from initial generation and recording through processing (including transformation or migration), use, retention, archiving and retrieval’.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.

Subscribe now Already a subscriber? Sign in here.

You may also like